Verition Fund Management LLC Decreases Stake in Catalent, Inc. (NYSE:CTLT)

Verition Fund Management LLC cut its stake in shares of Catalent, Inc. (NYSE:CTLT) by 12.9% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 364,683 shares of the company’s stock after selling 53,864 shares during the quarter. Verition Fund Management LLC owned about 0.20% of Catalent worth $22,089,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Brooklyn Investment Group acquired a new position in Catalent during the third quarter worth $31,000. Thurston Springer Miller Herd & Titak Inc. acquired a new position in shares of Catalent during the 2nd quarter worth $42,000. Sentry Investment Management LLC purchased a new stake in shares of Catalent in the 3rd quarter worth about $53,000. Longfellow Investment Management Co. LLC grew its stake in Catalent by 45.7% in the 2nd quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock valued at $55,000 after acquiring an additional 305 shares during the last quarter. Finally, GAMMA Investing LLC increased its holdings in Catalent by 25.9% during the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock valued at $58,000 after acquiring an additional 212 shares in the last quarter.

Analyst Ratings Changes

Several brokerages have issued reports on CTLT. StockNews.com downgraded shares of Catalent from a “hold” rating to a “sell” rating in a report on Friday, November 22nd. William Blair reaffirmed a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. Baird R W downgraded Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Finally, Robert W. Baird reissued a “neutral” rating and issued a $63.50 price target on shares of Catalent in a report on Tuesday, September 24th. One research analyst has rated the stock with a sell rating and seven have issued a hold rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $63.40.

Catalent Stock Up 0.2 %

CTLT stock opened at $61.12 on Friday. The company has a 50 day moving average price of $59.90 and a two-hundred day moving average price of $58.47. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51. The stock has a market capitalization of $11.09 billion, a P/E ratio of -27.04, a PEG ratio of 2.42 and a beta of 1.16. Catalent, Inc. has a one year low of $36.74 and a one year high of $61.50.

Catalent (NYSE:CTLT) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.06 billion. During the same period in the prior year, the firm earned ($0.10) EPS. Catalent’s revenue for the quarter was up 4.2% on a year-over-year basis. As a group, sell-side analysts expect that Catalent, Inc. will post 0.84 EPS for the current year.

Insider Buying and Selling

In related news, Director Michelle R. Ryan sold 2,800 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the transaction, the director now directly owns 10,835 shares of the company’s stock, valued at approximately $646,849.50. This trade represents a 20.54 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider David Mcerlane sold 1,994 shares of the business’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the sale, the insider now directly owns 36,304 shares of the company’s stock, valued at approximately $2,177,150.88. This trade represents a 5.21 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 5,114 shares of company stock valued at $305,931. Insiders own 0.31% of the company’s stock.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.